ABS0543 INTERIM ANALYSIS OF A EUROPEAN REAL-WORLD STUDY ON THE EFFECTIVENESS, PHYSICIAN SATISFACTION, AND PATIENT CHARACTERISTICS IN PSORIATIC ARTHRITIS TREATED WITH BIMEKIZUMAB: INSIGHTS FROM GERMANY, SPAIN, AND THE UNITED KINGDOM

<h2>Abstract</h2><h3>Background:</h3> Psoriatic arthritis (PsA) is a chronic inflammatory disease, characterised by inflammatory arthritis associated with psoriasis (PsO) [1]. Bimekizumab (BKZ) is a humanised monoclonal IgG1 antibody that acts by selectively inhibiting interleukin (IL)-17F in addition to IL-17A and has demonstrated long-term clinical efficacy and safety in patients with PsA [2, 3]. BKZ was approved for the treatment of PsA in Europe in 2023 [4]. Research in real-world settings can complement findings from randomised controlled trials by evaluating the effectiveness of treatments in a broader population. <h3>Objectives:</h3> To assess effectiveness, patient characteristics, treatment history, disease severity, and physician satisfaction among patients with PsA treated with BKZ, from a real-world cross-sectional study. <h3>Methods:</h3> Interim data were drawn from the Adelphi Real World BKZ PsA Plus Disease Specific Programme™, an ongoing cross-sectional survey, with elements of retrospective data collection from rheumatologists and dermatologists, and their consulting patients with PsA undergoing BKZ treatment. This is a multinational survey being conducted in France, Germany, Italy, Spain, the United Kingdom (UK), Canada, Japan, and the United States of America. Data collection began in July 2024, following a staggered approach by country based on BKZ reimbursement, and is expected to be complete in September 2025. Interim data from Germany, Spain and the UK is presented in this abstract. Physicians reported details of demographics, treatment history, perceived overall disease severity and skin severity, and their own satisfaction with the control provided by BKZ. Physician-reported severity and treatment satisfaction data were stratified by BKZ treatment duration (<3 months, 3–6 months, >6 months). No inclusion criteria relating to treatment duration were imposed. All analyses were descriptive and data were reported as observed; no imputation of missing values was performed. <h3>Results:</h3> Demographics, disease duration and treatment history for all patients with PsA treated with BKZ (n=342) are described in the Table 1. The sample was comprised of patients from Germany (35%), Spain (40%) and the UK (25%), with 80% of patients having a diagnosis of PSO prior to PsA. Participating rheumatologists (n=72) and dermatologists (n=27) reported that all patients had moderate-to-severe disease at BKZ initiation. At the most recent consultation, in patients who had been prescribed BKZ for <3 months, 3–6 months, or >6 months, 21%, 61%, and 80% of patients, respectively, were perceived by their physician to have mild disease severity (Figure 1A). In patients who had received at least 3 months of treatment, only 1% were perceived as having severe disease. The proportion of patients with no skin symptoms increased from 4% at BKZ initiation to 18% at the most recent consultation for patients prescribed BKZ for <3 months, increased from 3% to 29% for those prescribed BKZ for 3–6 months, and increased from 1% to 40% for those prescribed BKZ for >6 months (Figure 1B). At the most recent treatment consultation, in patients who had been prescribed BKZ for <3 months, 3-6 months, or >6 months, 76%, 97% and 98% of physicians, respectively, reported they were satisfied or very satisfied with the treatment (Figure 1C). <h3>Conclusion:</h3> In real-world settings, both physician-perceived overall disease severity and skin severity improved in patients with PsA treated with BKZ. A high proportion of physicians were satisfied with the control of PsA provided by BKZ in their patients, with nearly all physicians reporting satisfaction with treatment for patients that had been prescribed BKZ for at least 3 months. These findings confirm the effectiveness of BKZ in PsA in routine clinical practice. <h3>REFERENCES:</h3> [1] FitzGerald O, Ogdie A, Chandran V, Coates LC, Kavanaugh A, Tillett W, Leung YY, deWit M, Scher JU, Mease PJ. Nature reviews Disease primers 2021;7(1):59. [2] Glatt S, Baeten D, Baker T, Griffiths M, Ionescu L, Lawson AD, Maroof A, Oliver R, Popa S, Strimenopoulou F, Vajjah P. Annals of the rheumatic diseases 2018;77(4):523-32. [3] Mease PJ, Merola JF, Tanaka Y, Gossec L, McInnes IB, Ritchlin CT, Landewé RB, Asahina A, Ink B, Heinrichs A, Bajracharya R. Rheumatology and Therapy 2024;11(5):1363-82. [4] UCB Pharma S.A. Bimzelx© (bimekizumab): Summary of Product Characteristics. 2023. https://www.ema.europa.eu/en/medicines/hu man/EPAR/bimzelx (accessed: 28 November 2024). <h3>Acknowledgements:</h3> Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the BKZ PsA Plus Disease Specific Programme (DSP)™. The DSP is a wholly owned Adelphi product and is the intellectual property of Adelphi Real World. The analyses described here were funded by UCB and used data from the Adelphi BKZ PsA Plus DSP. UCB was one of multiple subscribers to the DSP and did not influence the original survey through either contribution to the design of questionnaires or data collection. Publication coordination was provided by Costello Medical and supported by UCB. <h3>Disclosure of Interests:</h3> Fabian Proft Speakers bureau with payments made directly to FP from AbbVie, AMGEN, BMS, Celgene, Eli Lilly, Hexal, Janssen, Medscape, MSD, Novartis, Pfizer, Roche and UCB, Consultancy with payments made directly to FP from AbbVie, BMS, Janssen, Novartis, Pfizer and UCB, Grant/research support from Novartis, Eli Lilly and UCB with payments made via FP's institution, Bruce Kirkham Speaker for Abbvie, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer and UCB, Consultant for Eli Lilly, Novartis, Pfizer and UCB, Grant/research support from Eli Lilly, Rubén Queiro Paid instructor for Abbvie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Speaker for Abbvie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB, Consultant for Abbvie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB, Grant/research support from Abbvie, Janssen and Novartis, Isabel Truman Employee of Adelphi Real World, Dan Twigg Employee of Adelphi Real World, Hervé Besson Shareholder of UCB, Employee of UCB, Helena Roque Employee of UCB. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.